Successful Use of lenacapavir and cabotegravir/rilpivirine for virologic suppression in pregnancy: A Case Report
Abstract
This case report describes the first documented use of lenacapavir in the setting of Y188L NNRTI resistance mutation during pregnancy, resulting in successful maternal viral suppression and prevention of vertical transmission of HIV. A 24-year-old woman with prior poor adherence, socioeconomic instability, and NNRTI resistance (Y188 L mutation) presented with uncontrolled viremia during her second pregnancy. After consultation with perinatal HIV experts, she initiated a long-acting injectable regimen combining lenacapavir (927 mg subcutaneous every 6 months) and cabotegravir/rilpivirine (600/900 mg intramuscular every 2 months). Rapid viral load reduction was achieved, declining from 147,351 to 67 copies/mL within weeks. Despite transient hepatotoxicity, the patient delivered an HIV-negative infant at term. Maternal HIV RNA remained
Fields of Study & Subjects
HIV/AIDS drug development and treatment
HIV/AIDS Research and Interventions
HIV Research and Treatment
Publication details
- Journal / source
- International Journal of STD & AIDS
- Publisher
- SAGE Publications
- Volume
- 37
- Issue
- 6
- Pages
- 671–673
- Publication date
- 16 January 2026
- Language
- EN